Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews

BMC Infectious Diseases

Karen R Steingart¹  Heather Blunt²  Karen Odato²  Elizabeth A Talbot³  Lisa V Adams³ 

[1] Cochrane Infectious Diseases Group, Liverpool, UK;Biomedical Libraries, Geisel School of Medicine at Dartmouth, 37 Dewey Field Road, Hanover, NH 03755, USA;Infectious Disease and International Health Section, Department of Medicine, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH 03755, USA

关键词: Latent tuberculosis infection;    Adherence;    HIV;    Tuberculosis;   

Others  :  1127727
DOI  :  10.1186/1471-2334-14-281

 received in 2014-04-26, accepted in 2014-05-14,  发布年份 2014

【 摘 要 】

Background

Uptake of isoniazid preventive therapy (IPT) to prevent tuberculosis has been poor, particularly in the highest risk populations. Interventions to improve IPT delivery could promote implementation. The large number of existing systematic reviews on treatment adherence has made drawing conclusions a challenge. To provide decision makers with the evidence they need, we performed an overview of systematic reviews to compare different organizational interventions to improve IPT delivery as measured by treatment completion among those at highest risk for the development of TB disease, namely child contacts or HIV-infected individuals.

Methods

We searched the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE), and MEDLINE up to August 15, 2012. Two authors used a standardized data extraction form and the AMSTAR instrument to independently assess each review.

Results

Six reviews met inclusion criteria. Interventions included changes in the setting/site of IPT delivery, use of quality monitoring mechanisms (e.g., directly observed therapy), IPT delivery integration into other healthcare services, and use of lay health workers. Most reviews reported a combination of outcomes related to IPT adherence and treatment completion rate but without a baseline or comparison rate. Generally, we found limited evidence to demonstrate that the studied interventions improved treatment completion.

Conclusions

While most of the interventions were not shown to improve IPT completion, integration of tuberculosis and HIV services yielded high treatment completion rates in some settings. The lack of data from high burden TB settings limits applicability. Further research to assess different IPT delivery interventions, including those that address barriers to care in at-risk populations, is urgently needed to identify the most effective practices for IPT delivery and TB control in high TB burden settings.

【 授权许可】

   
2014 Adams et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, 1:CD000171.
• [2]Curry FJ: Prophylactic effect of isoniazid in young tuberculin reactors. N Engl J Med 1967, 277:562-567.
• [3]Hsu KH: Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA 1974, 229:528-533.
• [4]Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E: Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013, 68(3):247-255.
• [5]World Health Organization: Guidance for national tuberculosis programmes on the management of tuberculosis in children – 2nd ed.. Geneva: World Health Organization; 2014. http://www.who.int/tb/challenges/childhood_tb_informationsheet.pdf webcite
• [6]van Wyk SS, Reid AJ, Mandalakas AM, Enarson DA, Beyers N, Morrison J, Hesseling AC: Operational challenges in managing Isoniazid Preventive Therapy in child contacts: a high-burden setting perspective. BMC Public Health 2011, 11:544. BioMed Central Full Text
• [7]Bristow CC, Larson E, Vilakazi-Nhlapo AK, Wilson M, Klausner JD: Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa. Int J Tuberc Lung Dis 2012, 16(8):1020-1022.
• [8]Chehab JC, Vilakazi-Nhlapo K, Vranken P, Peters A, Klausner JD: Survey of isoniazid preventive therapy in South Africa, 2011. Int J Tuberc Lung Dis 2012, 16(7):903-907.
• [9]Lewin S, Munabi Babigumira S, Glenton C, Daniels K, Bosch Capblanch X, Van Wyk BE, Odgaard Jensen J, Johansen M, Aja GN, Zwarenstein M, Scheel IB: Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database Syst Rev 2010, (3):CD004015. doi:10.1002/14651858.CD004015.pub3
• [10]Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
• [11]Dodds F, Rebair-Brown A, Parsons S: A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication. Clin Effect Nurs 2000, 4:47-53.
• [12]Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, Kimber A, Shaw K, Walker J: Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. Health Technol Assess 2001, 5:1-79.
• [13]Sharp J, Wild MR, Gumley AI: A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis. Am J Kidney Dis 2005, 45:15-27.
• [14]Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F: Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry 2003, 64:1415-1420.
• [15]M’Imunya JM, Kredo T, Volmink J: Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev 2012, (5):CD006591. doi:10.1002/14651858.CD006591.pub2
• [16]Lutge EE, Wiysonge CS, Knight SE, Volmink J: Material incentives and enablers in the management of tuberculosis. Cochrane Database Syst Rev 2012, 1:CD007952.
• [17]van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J: Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res 2007, 7:55. BioMed Central Full Text
• [18]Cochrane Effective Practice and Organisation of Care Review Group, Data Collection Checklist. 2002. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf webcite
• [19]Smith V, Devane D, Begley CM, Clarke M: Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011, 11(1):15. BioMed Central Full Text
• [20]Becker LA, Oxman AD, Chapter 22: Overviews of reviews. In Cochrane Handbook for Systematic Reviews of Interventions Edited by Higgins JPT, Green S. 2008. [Version 22.20 22.21 5.0.1 [updated September 2008]. The Cochrane Collaboration] http://www.cochrane-handbook.org webcite
• [21]World Health Organization: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011.
• [22]American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000, 49(RR-6):151.
• [23]Al-Darraji HAA, Kamarulzaman A, Altice FL: Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis 2012, 16(7):871-879.
• [24]DeFulio A, Silverman K: The use of incentives to reinforce medication adherence. Prev Med 2012, 55(Suppl):S86-S94.
• [25]Uyei J, Coetzee D, Macinko J, Guttmacher S: Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2011, 11(11):855-867.
• [26]Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008, 12(11):1235-1254.
• [27]Zuñiga JA: Medication adherence in Hispanics to latent tuberculosis treatment: a literature review. J Immigr Minor Health 2012, 14(1):23-29.
• [28]Hopkins A, Solomon J, Abelson J: Shifting boundaries in professional care. J R Soc Med 1996, 89(7):364-371.
• [29]Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007, 7:10. BioMed Central Full Text
• [30]World Health Organization: Global tuberculosis report 2013; WHO report. Geneva: World Health Organization; 2013. WHO/HTM/TB/2013.11
• [31]Ryan R, Santesso N, Hill S, Lowe D, Kaufman C, Grimshaw J: Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews. Cochrane Database Syst Rev 2011., (5) Art. No.: CD007768. doi:10.1002/14651858.CD007768.pub2